Table 1.

Descriptive statistics for primary analysis cohort (n = 67). Baseline characteristics were compared between treatment groups using either chi-square of Fisher exact tests for categorical factors and t-tests or Wilcoxon rank-sum tests for continuous factors.

ControlTreatmentTotalp
N (%)33 (49)34 (51)67
Sex (%)0.24
  Women2 (100)0 (0)2
  Men31 (48)34 (52)65
Inflammatory (%)0.38
  Yes12 (43)16 (57)28
  No21 (54)18 (46)39
Age, yrs, mean (SD)63.2 (12.4) n = 3365.3 (11.6) n = 3464.3 (11.9) n = 670.49
Disease duration, yrs, median (minimum, maximum)12.5 (0.3, 40) n = 3018.5 (0.3, 51) n = 2614 (0.3, 51) n = 560.44+
Baseline WOMAC pain score, mean (SD)10.1 (3.3) n = 3310.8 (3.2) n = 3410.5 (3.2) n = 670.36
4-week WOMAC pain score, mean (SD)10.0 (3.2) n = 338.75 (4.0) n = 349.4 (3.6) n = 670.16
Baseline WOMAC total score, mean (SD)45.3 (15.6) n = 3251.6 (15.0) n = 3348.5 (15.5) n = 650.10
4-week WOMAC total score, mean (SD)45.8 (15.9) n = 3142.6 (19.6) n = 3244.1 (17.8) n = 630.48
Baseline VAS score, mean (SD)4.7 (2.6) n = 325.0 (2.6) n = 324.9 (2.6) n = 640.64
4-week VAS score, mean (SD)4.8 (2.6) n = 293.7 (2.4) n = 324.3 (2.5) n = 610.08
  • WOMAC: Western Ontario and McMaster Universities Index; VAS: visual analog scale, for physician global assessment.